More about Dr. Lal PathLabs Limited
Fundamentals for Dr. Lal PathLabs Limited
Regulatory Filings for Dr. Lal PathLabs Limited
The Renewable Success Story Beyond Solar
Startups Mint India’s New Billionaires
India's Biggest IPO Has a Bigger Meaning
From Watches to Wealth: Titan's New Empire
Fundamentals for Dr. Lal PathLabs Limited
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.
Revenue projections:
Revenues for Dr. Lal PathLabs Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.
Financial Ratios:
| currentRatio | 3.476000 |
|---|---|
| forwardPE | 41.047497 |
| debtToEquity | 7.831000 |
| earningsGrowth | -0.154000 |
| revenueGrowth | 0.166000 |
| grossMargins | 0.624340 |
| operatingMargins | 0.202360 |
| trailingEps | 31.590000 |
| forwardEps | 41.196180 |
LALPATHLAB's current ratio of 3.476 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, LALPATHLAB can comfortably cover its liabilities, reflecting a strong financial outlook.
LALPATHLAB's low earnings and revenue growth suggest shrinking profits. This negative trend could indicate that the company is struggling to maintain its financial performance and may face challenges ahead.
LALPATHLAB's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
Dr. Lal PathLabs Limited's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in Dr. Lal PathLabs Limited's earnings potential, suggesting stronger financial performance compared to the previous year.
Price projections:
LALPATHLAB's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.
Insider Transactions:
44 sales of Dr. Lal PathLabs Limited stock were made, with market price at 2677.8431812633166 per share.1 LALPATHLAB stock purchases took place, with market price of 3308.5.There is no noticeable trend in insider transactions, making it difficult to assess whether the company is headed in a positive or negative direction.
Recommendation changes over time:
The analysts' recent buy bias for Dr. Lal PathLabs Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Dr. Lal PathLabs Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
SEBI's New Gateway Is Rewiring Foreign Investment in India
Why Japan Backs India’s Truckers
India's $69B Eurasian Trade Power Play